Taken together, these results demonstrate a direct relationship between SP1 binding and PRKCB transcription, and further suggest that this TF is a contributor to the pathobiology of CLL and potentially other malignant cells where PKCβII is overexpressed. Here, PRKCB is linked to B-cell chronic lymphocytic leukemia.